banner
 
bar

program

slides
bar
 
 

Stroke Prevention in Atrial Fibrillation

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period November 16, 2012 through November 16, 2014, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 3 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

3.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in stroke prevention in atrial fibrillation

Release Date

November 16, 2012

Expiration Date

November 16, 2014

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoThis program is supported by educational grants from the Bristol-Meyers Squibb/Pfizer Cardiovascular Partnership

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

SAMUEL Z. GOLDHABER, MD
Program Chairman
Director, Venous Thromboembolism Research Group
Cardiovascular Division
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Consultant: Baxter, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Merck, Pfizer, Portola, Sanofi Aventis
Research Grants: Daiichi Sankyo, Eisai, EKOS, J&J, Sanofi Aventis



CHRISTIAN T. RUFF, MD, MPH
Associate Physician
Cardiovascular Division
Brigham and Women’s Hospital
Instructor in Medicine
Harvard Medical School
Boston, MA

Grant Research: Daiichi-Sankyo (Investigator of AF Trial)


ELAINE M. HYLEK, MD, MPH
Professor of Medicine
Department of Medicine
Boston University School of Medicine
Director, Thrombosis Clinic and Anticoagulation Service

Consultant: Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer, Johnson & Johnson
Grant Research: Orbit AF Registry, Aristotle Trial
Executive Steering Committee: Orbit AF Registry, Aristotle Trial

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand advances in oral anticoagulation based on new mechanisms involving inhibition of targeted factors in the coagulation cascade; and the possible implications of these advances for prophylaxis of arterial thromboembolism and stroke in the setting of atrial fibrillation;
  • Apply national guidelines-including those issues by the ACC, AHA, ASA, ACCP, and others-so that clinicians can overcome practice gaps and improve thrombosis management and outcomes in patients with AF and other risk factors for stroke;
  • Detail how systemic anticoagulation with established and novel, non-monitored anticoagulants (NMOACs), when aligned with specific risk scores for AF, including CHADS2, CHA2DS2-VASc, and HAS-BLED, can reduce risk of stroke in the setting of AF; and, as a result become more clinically skilled at using multiple approaches, including established VKA-based treatment, and new, evidence-based, guideline-sanctioned approaches affecting other targets in the coagulation cascade;
  • Describe epidemiology, scope of problem, risk stratification (CHADS2), landmark trials, national guidelines, and the multidimensional therapeutic landscape of antithrombotic strategies shown to be useful for stroke risk reduction in AF; and, as result, become more clinically skilled at intervening in appropriately risk-stratified patients, in order to improve clinical outcomes in patients at risk of stroke in the setting of AF;
  • Understand the mechanisms involved in thromboembolic prevention in AF, and how new agents employing these mechanisms, with predictable anticoagulation, in the absence of clinical monitoring, fit into the treatment algorithms for SPAF

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACT
alemtuzumab
Avonex
Axonal
Azathioprine
Behçet
BENEFIT
betaseron
BEYOND
Brain Atrophy
brain stem
CD4+ T
cerebellum,
spinal cord
cerebral cortex
Cladribine
CHAMPIONS
CHAMPS/ETOMS

Copaxone
Corticosteroids
Cyclophosphamide
daclizumab
Demyelination
DMD
EDSS
EVIDENCE
Fingolimod
Glatiramer acetate
HIV
HTLV-1
Human IgG4IFN b-1a
IFN b-1b
Immunosuppression
Laquinimod
INCOMIN

Interferon
Lesions
Lyme disease
Methotrexate
Mitoxantrone
MRI
Multiple Sclerosis
relapsing-remitting MS
Mycophenolate mofetil
Natalizumab
neuritic transection
neurodegenerative
Neuroimmunomodulating
neuroimmunomodulation
Neurosyphilis
NIMO
NMSS
Novantrone

optic nerves
periventricular
PML
PRECISE
PRISMS
Rebif
REGARD
rituximab
RRMS
Sarcoidosis
Selective adhesion molecule inhibitor
Sjögren syndrome
Statins
Teriflunomide
Tysabri
white matter